ExaGrid Announces New Software Version 6.0
ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the release of software Version 6.0, which begins shipping on September 18, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005278/en/
Key features include:
New Retention Time-Lock for Ransomware Recovery
Retention Time-Lock is a revolutionary approach to protecting backup retention data to enable fast and easy recovery from ransomware.
- ExaGrid’s two-tier architecture includes a network-facing tier and a non-network-facing tier. ExaGrid alone controls the non-network-facing tier, creating a tiered air gap.
- Backups are written to the network-facing-tier for fast backup performance. The most recent backups are kept in their full undeduplicated form for fast restores.
- Data is adaptively deduplicated (for storage cost efficiency) into the non-network-facing tier for long-term retention data. Organizations can have as many days, weeks, months, or years of retention as they require. There is no limit to the number of version retention copies that can be saved.
- In addition to the long-term retention, ExaGrid offers a policy-driven approach allowing for any delete requests issued to the network-facing tier to be delayed in the non-network-facing tier for a specified number of days, so that backup data will not be deleted when a hacker takes control of the backup application or backup storage.
- If encrypted data is sent to the network-facing tier, or if any of its data is encrypted, ExaGrid’s repository is protected as all the deduplication objects are immutable because they are never modified.
ExaGrid assumes the hackers will take control of the backup application or the backup storage and will issue delete commands for all backups. ExaGrid has the only non-network-facing tiered backup storage solution (a tiered air gap) with delayed deletes and immutable deduplication objects. This unique approach ensures when a ransomware attack occurs, data can be easily recovered or VMs booted from the ExaGrid Tiered Backup Storage system. Not only can the primary storage be restored, but all retained backups remain intact.
“ExaGrid’s Version 6.0 provides our customers with a new strategy for ransomware recovery: ExaGrid’s Retention Time-Lock, which prevents hackers from deleting data stored in our system’s repository tier as all deletes are delayed by a policy setting. This unique approach allows customers to recover data in the event that the primary storage has become compromised by ransomware or malware,” said Bill Andrews, ExaGrid’s President and CEO. “Unlike other approaches, which require the purchase of an additional storage unit, our approach only requires that customers allocate 2% to 10% of additional repository storage in their existing system with an adjustable delay period, which is in line with our goal of offering the most cost-effective solutions to our customers.”
Security Enhancements (in addition to Ransomware Recovery), New UI Platform, and Other Highlights of Version 6.0
Version 6.0 includes the following security enhancements:
- New security officer role governs any changes to the Retention Time-Lock policy
- Optional Two-Factor authentication in web-based user interface using any OAUTH-TOTP app
- Additional control over SSH access
- Utilize Active Directory credentials from trusted domains to control share and user interface access
- New operator role for day to day operations reduces the need for administrator access.
- Security checklist for quick and easy implementation of best practices
- Automatic user interface logout after a period of inactivity
Version 6.0 includes the following additional features:
- User interface improvements provide intuitive details about how the ExaGrid system’s storage capacity is being utilized
- Streamlined navigation experience
- Deduplication and replication performance improvements across multiple backup applications
ExaGrid’s Unique Approach: Tiered Backup Storage
Disk-cache Landing Zone (Performance Tier)
- ExaGrid writes directly to disk for the fastest backup performance
- ExaGrid restores directly from disk for the fastest restores and VM boots
Long-term Retention Repository (Retention Tier)
- ExaGrid tiers long-term retention to a deduplicated data repository to reduce storage and resulting storage costs
Backing up to low-cost disk is fast for backups and restores, however, with longer-term retention, the amount of disk required becomes extremely expensive.
To reduce the amount of disk for long-term retention, deduplication appliances reduce the amount of storage and cost, however the deduplication is performed inline on the way to the disk which slows down backups to about one-third the performance of disk. Also, the data is only stored in deduplicated format resulting in extremely slow restores and VM boots as the data has to be reassembled, or rehydrated, for each request. In addition, deduplication appliances are scale-up storage which only adds storage capacity as data grows, resulting in backup windows that continue to grow as data grows, expensive forklift upgrades, and forced product obsolescence.
ExaGrid Tiered Backup Storage writes directly to disk for the fastest backups, and restores directly from disk for the fastest restores and VM boots. ExaGrid then tiers the long-term retention data to a deduplicated data repository to reduce the amount of retention storage and resulting cost. In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory, and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades, and allows for mixing appliances of different sizes and models in the same scale-out system which eliminates product obsolescence while protecting IT investments up front and over time.
ExaGrid offers the best of both worlds by offering low-cost disk for the fastest backup and restore performance tiered to a deduplicated data repository for the lowest cost retention storage. The scale-out storage architecture provides a fixed-length backup window and is low cost up front and over time.
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our success stories.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX ® ▼ (daratumumab) Subcutaneous Formulation Regimen After First or Subsequent Relapse in Multiple Myeloma4.12.2020 20:52:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of the Phase 3 APOLLO study showing that the addition of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation to pomalidomide and dexamethasone (D-Pd) significantly reduced the risk of progression or death by 37 percent, compared to Pd alone in patients with multiple myeloma (MM) after the first or subsequent relapse of disease.1 The APOLLO results, which will be presented on Sunday, December 6 at 9:00 p.m. CET during the American Society of Hematology (ASH) 2020 Annual Meeting and featured in the ASH press briefing (Abstract #112), add to the body of evidence supporting treatment with daratumumab SC-based regimens for patients with relapsed MM. These data were the basis for recent regulatory submissions in Europe and the United States (U.S.) seeking approval for daratumumab SC in combination with Pd for the treatment of patients with relapsed or refractory MM, with two or more prior lines of therapy, includi
Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World4.12.2020 17:36:00 CET | Press release
Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors. Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global healthcare crisis in more than a century. 2020 was an opportunity for the world to “test drive the future” and make way for growth as the pandemic ebbs. The tailwinds for 2021 are underappreciated: our financial system is strong, government actions to protect individuals and businesses have been effective, technological
Takashi Nagao Appointed President and Chief Executive Officer of Medicago4.12.2020 17:00:00 CET | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today. Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond
WorldRemit Leads the Way Offering a USD Payout Option in Nigeria4.12.2020 16:46:00 CET | Press release
WorldRemit, a leading digital cross-border payments business has announced that its customers in Nigeria can now receive remittances in foreign currency (USD) through its cash pick up providers. Following the announcement of the Central Bank of Nigeria (CBN) a day before, WorldRemit quickly adapted to the new requirements making it the first digital service to offer its customers worldwide the option of cash pickup in USD in Nigeria. WorldRemit enables Nigerians in over 50 countries around the world to support their family and friends in Nigeria. The decision by the Central Bank of Nigeria (CBN) to allow international money transfers to be paid in foreign currency, is aimed at providing increased liquidity in the foreign exchange market. The bank explained that the new regulation is part of its efforts to liberalize, simplify and improve the receipt and administration of diaspora remittances into Nigeria. Gbenga Okejimi, Country Manager, Nigeria and Ghana, at WorldRemit, said:“ We are
PPC Upgraded to ‘B’ with ‘Stable’ Outlook by S&P4.12.2020 15:16:00 CET | Press release
In its annual research update released on 27 November 2020, S&P upgraded PPC’s stand-alone credit profile (SACP) upward by two notches to ‘B’ from ‘CCC+’, resulting in an overall upgrade of the long-term credit rating of PPC to ‘B’ from ‘B-‘. According to S&P the two notch upgrade in PPC’s standalone corporate rating confirms that the Company’s strategic repositioning and the improved Greek energy market fundamentals have transformed its competitive position, reducing past concerns over its liquidity and long-term sustainability. The ‘Stable’ outlook underscores S&P’s expectation that PPC will continue to deliver on its transformation plan, with solid liquidity and improved margins. PPC’s strategic plan to convert its generation mix toward lower carbon dioxide (CO2) emissions improve its fleet competitiveness and long-term prospects. As mentioned in their report, S&P expects a substantial increase in EBITDA and improvement in credit metrics on the back of higher profitability as PPC ac
Chengdu Launches Online Exhibition of History and Culture to Enhance Cultural Ties With European Countries4.12.2020 13:17:00 CET | Press release
The launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition was held by the Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office on 24 November. The event, along with the unveiling ceremony of Chengdu Chronicles Culture Overseas (Europe) Exchange Cooperation, were witnessed by distinguished guests in many European countries including the Netherlands, Germany and Belgium through video and online connections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005278/en/ On November 24, Gao Zhigang (center), Director of Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office, and other guests attend the launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition. (Photo: Business Wire) Chengdu History and Culture Overseas Virtual Exhibition will also be launched at major foreign media platforms for audiences all over the world. Gao ZhiGang, Director of Che
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 12:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom